Ergotamine has been used in clinical practice for the acute been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of For most migraine sufferers requiring a specific antimigraine treatment, a triptan is generally a better option migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have from both an efficacy and side-effect perspective.
Introduction
Ergotamine burst onto the medical scene during the Middle first isolated by Stoll (1918) and has been used in the acute treatment of migraine since 1926 (Maier, 1926) , with Ages when mass poisoning by ergotamine occurred throughout Europe due to eating bread contaminated with no alternative specific acute anti-migraine treatment for decades. Remarkably, despite widespread use, there is little the sclerotia of the mushroom Claviceps purpurea, which is a parasite on rye, wheat, barley and other cultivated consensus as to its place in practice. In this review, we attempt to set out information concerning ergotamine and grains, climaxing in St Anthony's Fire. Due to its remarkable uterotonic and vasoconstrictor effects, ergotamine was then make conclusions concerning its use based on current evidence. The American Academy of Neurology has used to precipitate childbirth and to control post-partum haemorrhage, first mentioned clearly by John Stearns in published recommendations on ergotamine use (Quality Standards Subcommittee of the American Academy of 1808 in a letter published in the Medical Repository of New York (Thoms, 1931) . The evolution of the use of Neurology, 1995) , but here we sought to provide detailed evidence for our position. Most clinicians feel ergotamine ergot derivatives in obstetric practice is covered elsewhere (Moir, 1974 ). An extract of ergot was used in clinical has some place in treating acute migraine, and we have attempted a consensus to present the core of its role. practice by Eulenberg (1883) , and ergotamine itself was Leysen et al., 1996; d Adham et al., 1993; e Hoyer, 1998 ; f Glusa and Roos, 1996; g Hoyer et al., 1994; Leysen and Gommeren, 1984 .
Pharmacology of ergotamine Effects on blood vessels
The most important and conspicuous pharmacological effect
Receptor binding profile and mode of action of ergot alkaloids is undeniably the vasoconstrictor action The ergot alkaloids have a complex mode of action that (Müller-Schweinitzer and Weidmann, 1978;  Müller-involves interaction with a variety of receptors. Indeed, as Schweinitzer, 1992) . Extensive studies in animals show that shown in Table 1 (Leysen and Gommeren, 1984; Hoyer, this vasoconstrictor effect is particularly marked within the 1988; Adham et al., 1993; Hoyer et al., 1994; Glusa and carotid vascular bed and the selectivity extends to the Roos, 1996; Leysen et al., 1996) , both ergotamine and arteriovenous anastomotic part; blood flow to a number of dihydroergotamine have affinities for 5-HT (5-hydroxytissues, including that to the brain, is little affected (Johnston tryptamine), dopamine and noradrenaline receptors. In and Saxena, 1978; De Vries et al., 1998) . Similar contrast, sumatriptan and the newer triptans are much more vasoconstrictor effects on cephalic arteriovenous anastomoses selective, showing high affinity for 5-HT 1B and 5-HT 1D are also observed with sumatriptan as well as with other receptors and a moderate affinity for 5-HT 1A and 5-HT 1F triptans (Saxena and Ferrari, 1996) . receptors .
In humans, ergotamine can constrict several isolated blood The α-adrenoceptor-blocking property of ergotamine, first vessels, including the pulmonary (Cortijo et al., 1997), described by Dale (Dale, 1906) , is textbook knowledge cerebral (Müller-Schweinitzer, 1992) , temporal (Østergaard (Hoffman and Lefkowitz, 1996). However, this property is et al., 1981) and coronary (MaassenVanDenBrink et al., often overemphasized, since it is observed only with high 1998) arteries. The drug seems to be more active on large doses used in some animal experiments and bears no relevance arteries (conducting vessels) than on arterioles (resistance to therapeutic use in humans. In lower therapeutically relevant vessels). Basal cerebral (Andersen et al., 1987; Dixon et al., concentrations, ergotamine acts as an agonist at α-adreno-1997) or myocardial (Gnecchi-Ruscone et al., 1998) blood ceptors, 5-HT (particularly 5-HT 1B/1D ) and dopamine D 2 flow may not change, although ergotamine does affect receptors (Müller-Schweinitzer and Weidmann, 1978; Saxena coronary vasodilator reserve (Gnecchi-Ruscone et al., 1998). and Cairo-Rawlins, 1979; Müller-Schweinitzer, 1992; Arterial blood pressure is moderately increased in therapeutic Vries et al., 1998; Villalón et al., 1999) . In addition, there is doses (Bulow et al., 1986; Dixon et al., 1997 ). An important evidence that both ergotamine and dihydroergotamine can feature of ergotamine and dihydroergotamine, as illustrated activate novel, as yet uncharacterized receptors (De Vries et al., 1998) .
in Fig. 1 (MaassenVanDenBrink et al., 1998) , is that their clarithromycin (Horowitz et al., 1996) and ritonavir (Liaudet et al., 1999) . Since the same cytochrome P450 enzyme metabolizes a number of other drugs, including bromocriptine, dexamethasone, ethinyloestradiol, ketoconazole, nifedipine, omeprazole and verapamil (Christians et al., 1996) , this interaction may extend to these drugs as well.
Ergotamine formulations
Most formulations of ergotamine are not very useful due to an inappropriate amount of ergotamine or compounding with (Dahlof, 1993) stated that 'there Ergotamine and dihydroergotamine have been reported to is little evidence that it is significantly more effective than inhibit dural plasma extravasation after stimulation of the placebo' and further 'the recommended doses of ergotamine trigeminal ganglion in rats (Buzzi and Moskowitz, 1991;  cannot be justified'. Despite the limited number of studies Buzzi et al., 1991) . In addition, as has been demonstrated with contemporary methodology that involve ergotamine for dihydroergotamine (Goadsby and Edvinsson, 1993;  (The International Headache Society Committee on Clinical Hoskin et al., 1996) , ergotamine derivatives may block the Trials in Migraine, 1991), there is evidence for the efficacy trigeminovascular pathway centrally. Ergotamine also has a of ergotamine in the literature, and this will be summarized prominent uterotonic action (Graves, 1996) . briefly here.
Pharmacokinetics of ergotamine Randomized controlled clinical trials with
Oral absorption of ergotamine is 60-70%, and the concurrent administration of caffeine improves both the rate and extent ergotamine A summary of 18 controlled double-blind trials of oral of absorption. Due to high first-pass metabolism, ergotamine has a very low bioavailability from oral administration.
ergotamine, or oral ergotamine plus caffeine, is given in Table 2 . In 10 trials (Ostfeld, 1961; Ryan, 1970 ; Waters, There is considerable subject variability with respect to bioavailability and lack of consistency in the clinical response 1970; Hakkarainen et al., 1979; Kinnunen et al., 1988; Sargent et al., 1988; Friedman et al., 1989 ; Cortelli et al., over multiple attacks. Compared with intravenous bioavailability (100%), oral bioavailability of ergotamine is 1996; McNeely and Goa, 1999; Reches and Eletriptan Steering Committee, 1999) ergotamine was compared with Ͻ1% (Sanders et al., 1983; Ibraheem et al., 1983) , rectal bioavailability is 1-3% and intramuscular bioavailability placebo, whereas in eight other trials ergotamine served as the standard comparative drug (Adams et al., 1971; Yuill is 47% (Tfelt-Hansen and Johnson, 1993) . Ergotamine is metabolized in the liver by largely undefined pathways; 90% et al., 1972; Hakkarainen et al., 1978 Hakkarainen et al., , 1980 Pradalier et al., 1985 ; The Multinational Oral Sumatriptan and Cafergot of the metabolites are excreted in the bile and the elimination half-life is 2 h (Tfelt-Hansen and Johnson, 1993 ). An interComparative Study Group, 1991; Treves et al., 1992; Le Jeunne et al., 1999) without placebo control. The initial dose action with erythromycin may dramatically increase the oral bioavailability of ergotamine (Francis et al., 1984) , and of ergotamine varied from 1 to 5 mg, and in several trials repeated intake of test drugs was used ( Table 2 ). The reported ergotism is a reported complication of co-administration with Tfelt-Hansen and Johnson (1993) . ASA ϭ aspirin; CASA ϩ M ϭ calcium carbasalate (equivalent to 900 mg of ASA) plus metoclopramide; DextC ϭ dextropropoxyphene compound; Diclo ϭ diclofenac; Erg ϭ ergotamine; ErgC ϭ ergotamine compound with caffeine (1 mg of ergotamine ϩ 100 mg of caffeine); Ergs ϭ ergostine (ϩ caffeine); Ele ϭ eletriptan; IsomC ϭ isometheptene compound; Napxs ϭ naproxen sodium; Pirp ϭ pirprofen; Sum ϭ sumatriptan; Tfa ϭ tolfenamic acid; Pl ϭ placebo; CO ϭ crossover; Pa ϭ parallel group; NS or ϭ ϭ no statistical significant difference; Ͼ ϭ more effective than. a Maximum number of attacks treated; b approximately one-quarter of patients did not have migraine (74); c only dose of isometheptene given (for other components, see reference); d verbal scale : 1 ϭ very mild, 2 ϭ mild, 3 ϭ moderate, 4 ϭ severe, 5 ϭ very severe; e only doses for dextropropoxyphene [65 mg of the chloride (9) or 100 mg of the napsylate (10)] are indicated (for other components, see references); f contains other components in addition to caffeine, see references; g study conclusions weakened by the lack of use of double dummy technique; h patients refractory to ergot therapy were excluded; i a decrease from severe or moderate headache to no or mild headache. parameters for efficacy were not all validated and varied Non-oral routes of administration considerably, from benefit based on a clinical interview Other routes of administration of ergotamine, which from a (Waters, 1970) to use of changes on a verbal headache scale kinetic point of view should be more efficacious, have (Yuill et al., 1972; Friedman et al., 1989 ; The Multinational scarcely been investigated. In one trial, inhaled ergotamine Oral Sumatriptan and Cafergot Comparative Study Group, (maximum dose of 1.8 mg) was found to be superior to 1991). Methodological flaws in some of these trials include sublingual ergotamine (maximum dose of 2 mg) which was the lack of clearly stated inclusion criteria, no reporting of no better than a sublingual placebo (Crooks et al., 1964) . In the baseline criteria and randomization procedures, unusual a double-blind placebo-controlled study, a suppository of design of some of the crossover trials with a variable ergotamine (2 mg) was no better than placebo, whereas number of attacks per patient, and superiority claims without ketoprofen (100 mg as a suppository) was superior to placebo appropriate statistics. (Kangasniemi and Kaaja, 1992) . In a recent randomized, Ergotamine (1-5 mg) was superior to placebo for some crossover, double-blind trial including 251 patients, so far parameters in seven trials (Ostfeld, 1961; Ryan, 1970;  published only on the Internet (1998), ergotamine plus Hakkarainen et al., 1979; Kinnunen et al., 1988 ; Sargent caffeine suppositories (2 and 100 mg, respectively) were et Friedman et al., 1989; Reches and Eletriptan superior to 25 mg sumatriptan suppositories, with response Steering Committee, 1999) and no better than placebo in rates of 73 and 63% respectively, after 2 h. Headache three studies using a dose of 2-3 mg (Waters, 1970; Cortelli recurrence (see below) occurred more frequently in et McNeely and Goa, 1999) . In two comparative sumatriptan-(22%) than in ergotamine-(11%) treated trials, ergotamine was superior to aspirin (500 mg) patients. However, significantly more patients preferred (Hakkarainen et al., 1978 (Hakkarainen et al., , 1980 , and was inferior to an sumatriptan suppositories (44%) than preferred ergotamine isometheptene compound in one trial (Yuill et al., 1972) and suppositories (36%), due to more side-effects after the latter. superior to it in another trial (Adams et al., 1971) . As shown Full publication of this study will be of great interest. in Table 2 , the drugs, such as ergocristine, tolfenamic acid, dextropropoxyphene, naproxen sodium, pirprofen and diclofenac, were generally found to be comparable with ergotamine, although there is one recent study of diclofenac
Headache recurrence with ergotamine
Headache recurrence can be defined as a return or worsening which showed superiority of this drug (Cortelli et al., 1999) . Exceptions are sumatriptan (100 mg orally) which was of the headache and associated migraine symptoms within 24-72 h after an initial medication-induced amelioration. It superior to 2 mg of ergotamine plus 200 mg of caffeine (The Multinational Oral Sumatriptan and Cafergot Comparative is a major issue for all acute migraine treatments, but has only been recognized during the clinical trial programme Study Group, 1991) , the combination of calcium carbasalate (equivalent to 900 mg of aspirin) and metoclopramide with subcutaneous sumatriptan (Visser et al., 1996c) . Recognition was triggered by the often dramatic contrast of (10 mg), which was superior to a rather small dose of 1 mg of ergotamine plus 100 mg of caffeine (Le Jeunne et al., an excellent initial improvement, which was followed by a rapid and very disappointing return of the headache after 1999), and eletriptan at 40 and 80 mg doses which were superior to 2 mg of ergotamine plus caffeine (Reches and 10-12 h. Subsequently, it has been observed that headache recurrence is common to all acute migraine treatments Eletriptan Steering Committee, 1999).
These trials of ergotamine, some of them placebo-(Ferrari, 1998), including ergotamine (The Multinational Oral Sumatriptan and Cafergot Comparative Study Group, 1991) , controlled, suggest that oral ergotamine is efficacious in the treatment of migraine but they do not quantify the benefit although some treatments are better than others in this regard. The mechanism of headache recurrence is unknown, but effectively. Thus no uniform picture of the utility of oral ergotamine emerges from these trials. Early use of ergotamine breakthrough of a temporarily suppressed migraine generator seems more likely than a new attack (Weiller et al., 1995 ; in migraine treatment was tried in two of the trials (Hakkarainen et al., 1978 (Hakkarainen et al., , 1980 in which the drugs were Visser et al., 1996a, b, c) . A longer drug plasma half-life does not reduce the incidence of headache recurrence, but administered as soon as the patients felt the onset of an attack. The results from this strategy are not convincing. The may delay the time to recurrence (Visser et al., 1996a) .
Where the risk of headache recurrence has been studied in use of escape medication is a clinically relevant efficacy parameter (The International Headache Society Committee sumatriptan users, it seems to be a patient-dependent rather than an attack-dependent phenomenon. About one-third of on Clinical Trials in Migraine, 1991) , and this was used by 31% (Kinnunen et al., 1988) , 44% (The Multinational Oral migraine patients using sumatriptan, especially those with long attacks of 2-3 days, will consistently experience Sumatriptan and Cafergot Comparative Study Group, 1991) and 46% (Ryan, 1970) of patients treated with ergotamine. No headache recurrence in each successfully treated attack, while patients with shorter attacks experience headache recurrence clinical trial data are available on within-subject consistency, which from results of pharmacokinetic studies and from only rarely (Visser et al., 1996b, c) .
A major point of discussion, even among the authors of clinical practice is probably poor compared with the use of triptans (Kramer et al., 1998; Pfaffenrath et al., 1998) .
the present review, is whether headache recurrence rates differ between drugs, and whether any differences have and ordinarily do not necessitate interruption of ergotamine therapy. clinical implications. The general perception is that, when effective, ergotamine carries a lower risk of headache In doses used in the treatment of migraine, the rectal administration of ergotamine produces little change in blood recurrence than the triptans. However, the questions arise as to whether this impression is correct, whether such a pressure but does cause a slowly progressing increase in peripheral arterial constriction that persists for up to 24 h comparison can actually be made and whether this also implies that patients who experience headache recurrence on (Bulow et al., 1986 ). triptans will not do so on ergotamine. The initial response, since a patient has to respond first in order to be at risk for headache recurrence, and the use of analgesics for early Cardiovascular side-effects treatment of recurring headache must be taken into account.
Ergotamine usually induces bradycardia even when the blood In addition, the time at which recurrence occurs must be pressure is not increased (Hoffman and Lefkowitz, 1996) . This considered, since headache is usually only monitored up to is due predominantly to increased vagal activity, but a reduction 24 h, although in an early direct comparison of rates of in sympathetic tone (by a central as well as peripheral recurrence at 48 h after dosing, a significant difference (P ϭ presynaptic action) and direct myocardial depression may also 0.009), reported to be 41% for oral sumatriptan 100 mg and be involved (Saxena and Cairo-Rawlins, 1979 ; Hoffman and 30% for patients treated with Cafergot (ergotamine 1 mg Lefkowitz, 1996) . Ergotamine can produce coronary plus caffeine, two tablets), was noted (The Multinational vasoconstriction, often with associated ischaemic changes and Oral Sumatriptan and Cafergot Comparative Study Group, anginal pain in patients with coronary artery disease (Galer 1991) . It is important to bear in mind that headache recurrence et al., 1991) . In contrast to triptans, the contractile effect of is assessed in a non-randomized population (responders to ergotamine in the human isolated coronary artery is longtreatment), and therefore an imbalance in the baseline clinical lasting and persists even after repeated washings (Fig. 1 ) characteristics cannot be excluded. As a result, simple (MaassenVanDenBrink et al., 1998) . Similarly, administration comparison of headache recurrence may be misleading.
of ergotamine (0.25 mg) intravenously caused a reduction in Instead of reporting response and recurrence rates separately, coronary microcirculatory blood flow as measured by PET overall efficacy might be better ascertained with a composite (Gnecchi-Ruscone et al., 1998) where, by contrast, sumatriptan measure which includes all the factors mentioned above.
produced no such change (Lewis et al., 1997) . Ideally, one would like to know how many patients require Ergotamine doses that produce peripheral vasoconstriction only one dose of medication to treat a migraine attack can also damage the capillary endothelium. The mechanism of effectively. This could be assessed with the so-called this toxic action is not clearly understood. Vascular stasis, 'complete response', which is the proportion of patients who thrombosis and gangrene are prominent features of ergot become pain-free within 2 h after drug administration and poisoning. The propensity of ergotamine to cause gangrene do not experience headache recurrence nor use analgesics in appears to parallel its vasoconstrictor activity (Peroutka, 1996) . the subsequent 24-72 h (sustained relief).
Uterine effects

Side-effect issues with ergotamine use
Ergotamine increases the motor activity of the uterus. After Ergotamine has a low degree of receptor selectivity which small doses, contractions are increased in force or frequency, increases the risk of experiencing a drug-induced side-effect or both, but are followed by a normal degree of relaxation. As (see above). Ergotamine often causes nausea and vomiting in the dose is increased, contractions become more forceful and a migraine sufferer and these are major clinical disadvantages prolonged, resting tonus is markedly increased, and sustained given the high prevalence of these symptoms during the contracture can result (Graves, 1996) . migraine attack. Nausea and vomiting occur in~10% of patients after oral administration of ergotamine and in about twice that number after parenteral administration. Nausea is Contraindications most probably caused by a direct effect on CNS emetic centres.
Ergotamine is contraindicated in women who are or may become pregnant, since the drugs may cause foetal harm. Ergotamine is also contraindicated in patients with peripheral vascular disease, coronary heart disease, uncontrolled
General side-effects
Weakness in the legs has been reported, and occasionally severe hypertension, stroke, impaired hepatic or renal function, and sepsis. Based on the theoretical additive pharmacological muscle pains have occurred in the extremities following ergotamine use. Numbness and tingling of the fingers and toes effects of the drugs, ergotamine should not be taken within 6 h of the use of triptans, and similarly triptans should not be are other reminders of the ergotism that this alkaloid may cause. Localized oedema and itching may occur in an occasional administered within 24 h of ergotamine. It also is recommended that ergotamine should not be used in complicated migraine hypersensitive patient. Most of these effects are not alarming 
Frequency of dosing:
• A major problem with ergotamine is ergotamine-induced headache and rebound headache 1/week or 6/month associated with frequent use. This can be limited by restricting ergotamine consumption and encouraging use of a preventative medication as headache becomes more frequent.
• May be modified to four consecutive doses for menstrual migraine • May be modified for use in cluster headache
Dose per attack:
Ergotamine should be dosed at one time as early as practicable in the attack at a dose that single dose (0.5-2 mg) produces a response with as few side-effects as possible. It is useful to test this dose for tolerability for nausea between attacks Preferred route: rectal Although still useful orally, ergotamine is generally better used, provided it is acceptable to the patient, by the rectal route because of improved absorption. Where it is available, the ergotamine puffer is preferred to the oral route for the same reasons (Peroutka, 1996) , migraine with prolonged aura, basal migraine headache pattern into what has been termed transformed migraine, but there is no consensus on this issue. or familial hemiplegic migraine.
When patients are abusing ergotamine, they fear the withdrawal headache and keep on taking ergotamine. This withdrawal headache is most likely a rebound headache since
Daily headache and ergotamine overuse
it occurs~24 h after the last intake of ergotamine, the normal It seems likely that any medication used for the treatment of duration of the vascular effect of a single dose (Bulow et al. , migraine attacks can be misused by being taken daily or almost 1986; Tfelt-Hansen and Johnson, 1993). The withdrawal daily (Diener and Tfelt-Hansen, 1993; Kaube et al., 1994;  headache is often so severe that the ergotamine abusers have Limmroth et al., 1999) . The problem with ergotamine overuse to be hospitalized in the withdrawal phase. Spontaneous with rebound headache was recognized by Graham in the late improvement is common after the medication is discontinued 1940s (Wolfson and Graham, 1949) and further clarified by (Diener and Tfelt-Hansen, 1993) . When ergotamine is Peters and Horton (Peters and Horton, 1951) and Friedman and discontinued, the prophylactic medications that previously colleagues (Friedman et al., 1955) . Why some patients are have been largely without benefit become more effective. The more prone to develop abuse and daily headache than others is prevention of ergotamine abuse is achieved primarily by unclear. Genetic and psychological factors seem to be involved.
restricting the frequency of intake to once per week, as a general Analgesic abuse as a major cause of chronic daily headache rule. Furthermore, patients should be carefully instructed to was recognized in the 1980s (Mathew et al., 1982;  Dichgans use ergotamine only for migraine attacks and not for tension et al., 1984) . type headaches. Migraine patients taking ergotamine daily suffer from several kinds of headaches (Diener and Tfelt-Hansen, 1993) : (i) a constant, diffuse, dull headache; (ii) a frequent throbbing When to use ergotamine-consensus headache in the early morning, sometimes combined with nausea, which disappears within 1 h after the intake of recommendations Despite the lack of consistent evidence for the efficacy of ergotamine and is probably a minor withdrawal headache; (iii) migraine attacks; and (iv) a withdrawal headache resembling ergotamine, we as clinicians are left to place the drug in a therapeutic context. Should ergotamine ever be used and if a severe and prolonged migraine attack with gradual return over weeks to the underlying headache pattern if ergotamine so, when? The writers take the view that there remains a place for ergotamine in modern clinical practice but only is stopped. In addition, the patients often have constant nausea, acrocyanosis and intermittent claudication due to ergotamine when used carefully. Many patients who would have received ergotamine in the 'pre-triptan' era are probably now better toxicity (von Storch, 1938) . Some authors (Mathew et al., 1982) have argued that ergotamine can change the primary off not being prescribed the drug. The recommendations for ergotamine is ineffective, a repeated dosing within half an hour is sometimes recommended, but we do not support this Cortelli P, Pierangeli G, Corsini R, Prologo G, Limido GL. Pain recommendation. This is partly for the reason that one simply control in migraine attacks: results from a double-blind, randomized, cannot expect onset of efficacy within this short time frame, within-patient, placebo-controlled trial comparing diclofenac-K and and thus this approach increases the risk for drug-induced ergotamine-caffeine. Cephalalgia 1996; 196: 359. side-effects. Table 3 summarizes a prudent use of ergotamine.
Cortijo J, Martí-Cabrera M, Bernabeu E, Domenech T, Bou J, Ultimately, physicians will decide to whom ergotamine all migraine sufferers, need medical review from time to time to ensure there are no issues of concern arising that
